Cullin4A and cullin4B are interchangeable for HIV Vpr and Vpx Action through the CRL4 ubiquitin ligase complex

Journal of Virology

Volumn 88, Issue 12, 2014, Pages 6944-6958

  Sharifi, Hamayun John ^a   Furuya, Andrea K M ^a   Jellinger, Robert M ^b   Nekorchuk, Michael D ^a   de Noronha, Carlos M C ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b ALBANY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRL4 UBIQUITIN PROTEIN LIGASE COMPLEX; CULLIN; CULLIN4A; CULLIN4B; GLYCOSIDASE; PROTEASOME; PROTEIN SAMHD1; PROTEIN VPX; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; URACIL N GLYCOSYLASE 2; VIRUS PROTEIN; VPR PROTEIN;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL FRACTIONATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME DEGRADATION; HEK293 CELL LINE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; IMMUNOPRECIPITATION; MACROPHAGE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; SIMIAN IMMUNODEFICIENCY VIRUS;

CELL CYCLE; CELL LINE; CULLIN PROTEINS; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; PROTEIN BINDING; UBIQUITIN-PROTEIN LIGASES; VIRAL REGULATORY AND ACCESSORY PROTEINS; VPR GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84901377734     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00241-14     Document Type: Article

References (108)

1. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF. 2003. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302:1056-1060. http://dx.doi.org/10.1126/science.1089591.
2. Stopak K, de Noronha C, Yonemoto W, Greene WC. 2003. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 12:591-601. http://dx.doi.org/10.1016/S1097-2765(03)00353-8.
3. Sheehy AM, Gaddis NC, Malim MH. 2003. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9:1404-1407. http://dx.doi.org/10.1038/nm945.
4. Marin M, Rose KM, Kozak SL, Kabat D. 2003. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 9:1398-1403. http://dx.doi.org/10.1038/nm946.
5. Conticello SG, Harris RS, Neuberger MS. 2003. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol. 13:2009-2013. http://dx.doi.org/10.1016/j.cub.2003.10.034.
6. Mehle A, Strack B, Ancuta P, Zhang C, McPike M, Gabuzda D. 2004. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 279: 7792-7798. http://dx.doi.org/10.1074/jbc. M313093200.
7. Mbisa JL, Barr R, Thomas JA, VandegraaffN, Dorweiler IJ, Svarovskaia ES, Brown WL, Mansky LM, Gorelick RJ, Harris RS, Engelman A, Pathak VK. 2007. Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plusstrand DNA transfer and integration. J. Virol. 81:7099-7110. http://dx.doi.org/10.1128/JVI.00272-07.
8. Chiu YL, Soros VB, Kreisberg JF, Stopak K, Yonemoto W, Greene WC. 2005. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature 435:108-114. http://dx.doi.org/10.1038/nature 03493.
9. Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, Malim MH. 2004. Cytidine deamination of retroviralDNAby diverseAPOBECproteins. Curr. Biol. 14:1392-1396. http://dx.doi.org/10.1016/j.cub.2004.06.057.
10. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L. 2003. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424:94-98. http://dx.doi.org/10.1038/nature01707.
11. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. 2003. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424:99-103. http://dx.doi.org/10.1038/nature01709.
12. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH. 2003. DNA deamination mediates innate immunity to retroviral infection. Cell 113:803-809. http://dx.doi.org/10.1016/S0092-8674(03)00423-9.
13. Mangeat B, Gers-Huber G, Lehmann M, Zufferey M, Luban J, Piguet V. 2009. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog. 5:e1000574. http://dx.doi.org/10.1371/journal.ppat.1000574.
14. Goffinet C, Allespach I, Homann S, Tervo HM, Habermann A, Rupp D, Oberbremer L, Kern C, Tibroni N, Welsch S, Krijnse-Locker J, Banting G, Krausslich HG, Fackler OT, Keppler OT. 2009. HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe 5:285-297. http://dx.doi.org/10.1016/j.chom.2009.01.009.
15. Mitchell RS, Katsura C, Skasko MA, Fitzpatrick K, Lau D, Ruiz A, Stephens EB, Margottin-Goguet F, Benarous R, Guatelli JC. 2009. Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking. PLoS Pathog. 5:e1000450. http://dx.doi.org/10.1371/journal.ppat.1000450.
16. Gupta RK, Hue S, Schaller T, Verschoor E, Pillay D, Towers GJ. 2009. Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion. PLoS Pathog. 5:e1000443. http://dx.doi.org/10.1371/journal.ppat.1000443.
17. Van Damme N, GoffD, Katsura C, Jorgenson RL, Mitchell R, Johnson MC, Stephens EB, Guatelli J. 2008. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3:245-252. http://dx.doi.org/10.1016/j.chom.2008.03.001.
18. Neil SJ, Zang T, Bieniasz PD. 2008. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451:425-430. http://dx.doi.org/10.1038/nature06553.
19. Goldstone DC, Ennis-Adeniran V, Hedden JJ, Groom HC, Rice GI, Christodoulou E, Walker PA, Kelly G, Haire LF, Yap MW, de Carvalho LP, Stoye JP, Crow YJ, Taylor IA, Webb M. 2011. HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature 480:379-382. http://dx.doi.org/10.1038/nature10623.
20. Ahn J, Hao C, Yan J, DeLucia M, Mehrens J, Wang C, Gronenborn AM, Skowronski J. 2012. HIV/simian immunodeficiency virus (SIV) accessory virulence factor Vpx loads the host cell restriction factor SAMHD1 onto the E3 ubiquitin ligase complex CRL4DCAF1. J. Biol. Chem. 287:12550-12558. http://dx.doi.org/10.1074/jbc. M112.340711.
21. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Segeral E, Yatim A, Emiliani S, Schwartz O, Benkirane M. 2011. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 474:654-657. http://dx.doi.org/10.1038/nature10117.
22. Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S, Florens L, Washburn MP, Skowronski J. 2011. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 474:658-661. http://dx.doi.org/10.1038/nature10195.
23. Lahouassa H, Daddacha W, Hofmann H, Ayinde D, Logue EC, Dragin L, Bloch N, Maudet C, Bertrand M, Gramberg T, Pancino G, Priet S, Canard B, Laguette N, Benkirane M, Transy C, Landau NR, Kim B, Margottin-Goguet F. 2012. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat. Immunol. 13:223-228. http://dx.doi.org/10.1038/ni.2236.
24. Elder RT, Yu M, Chen M, Zhu X, Yanagida M, Zhao Y. 2001. HIV-1 Vpr induces cell cycle G2 arrest in fission yeast (Schizosaccharomyces pombe) through a pathway involving regulatory and catalytic subunits of PP2A and acting on both Wee1 and Cdc25. Virology 287:359-370. http://dx.doi.org/10.1006/viro.2001.1007.
25. Gummuluru S, Emerman M. 1999. Cell cycle-and Vpr-mediated regulation of human immunodeficiency virus type 1 expression in primary and transformed T-cell lines. J. Virol. 73:5422-5430.
26. Stivahtis GL, Soares MA, Vodicka MA, Hahn BH, Emerman M. 1997. Conservation and host specificity of Vpr-mediated cell cycle arrest suggest a fundamental role in primate lentivirus evolution and biology. J. Virol. 71:4331-4338.
27. Zhao Y, Cao J, O'Gorman MR, Yu M, Yogev R. 1996. Effect of human immunodeficiency virus type 1 protein R (vpr) gene expression on basic cellular function of fission yeast Schizosaccharomyces pombe. J. Virol. 70:5821-5826.
28. Planelles V, Jowett JB, Li QX, Xie Y, Hahn B, Chen IS. 1996. Vprinduced cell cycle arrest is conserved among primate lentiviruses. J. Virol. 70:2516-2524.
29. He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR. 1995. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J. Virol. 69:6705-6711.
30. Di Marzio P, Choe S, Ebright M, Knoblauch R, Landau NR. 1995. Mutational analysis of cell cycle arrest, nuclear localization and virion packaging of human immunodeficiency virus type 1 Vpr. J. Virol. 69: 7909-7916.
31. Wen X, Duus KM, Friedrich TD, de Noronha CM. 2007. The HIV1 protein Vpr acts to promote G2 cell cycle arrest by engaging a DDB1 and Cullin4A-containing ubiquitin ligase complex using VprBP/DCAF1 as an adaptor. J. Biol. Chem. 282:27046-27057. http://dx.doi.org/10.1074/jbc. M703955200.
32. Tan L, Ehrlich E, Yu XF. 2007. DDB1 and Cul4A are required for human immunodeficiency virus type 1 Vpr-induced G2 arrest. J. Virol. 81:10822-10830. http://dx.doi.org/10.1128/JVI.01380-07.
33. Le Rouzic E, Belaidouni N, Estrabaud E, Morel M, Rain JC, Transy C, Margottin-Goguet F. 2007. HIV1 Vpr arrests the cell cycle by recruiting DCAF1/VprBP, a receptor of the Cul4-DDB1 ubiquitin ligase. Cell Cycle 6:182-188. http://dx.doi.org/10.4161/cc.6.2.3732.
34. Hrecka K, Gierszewska M, Srivastava S, Kozaczkiewicz L, Swanson SK, Florens L, Washburn MP, Skowronski J. 2007. Lentiviral Vpr usurps Cul4-DDB1[VprBP] E3 ubiquitin ligase to modulate cell cycle. Proc. Natl. Acad. Sci. U. S. A. 104:11778-11783. http://dx.doi.org/10.1073/pnas.0702102104.
35. DeHart JL, Zimmerman ES, Ardon O, Monteiro-Filho CM, Arganaraz ER, Planelles V. 2007. HIV-1 Vpr activates the G2 checkpoint through manipulation of the ubiquitin proteasome system. Virol. J. 4:57. http://dx.doi.org/10.1186/1743-422X-4-57.
36. Belzile JP, Duisit G, Rougeau N, Mercier J, Finzi A, Cohen EA. 2007. HIV-1 Vpr-mediated G2 arrest involves the DDB1-CUL4A(VPRBP) E3 ubiquitin ligase. PLoS Pathog. 3:e85. http://dx.doi.org/10.1371/journal.ppat.0030085.
37. Laguette N, Bregnard C, Hue P, Basbous J, Yatim A, Larroque M, KirchhoffF, Constantinou A, Sobhian B, Benkirane M. 2014. Premature activation of the SLX4 complex by Vpr promotes G2/M arrest and escape from innate immune sensing. Cell 156:134-145. http://dx.doi.org/10.1016/j.cell.2013.12.011.
38. Wen X, Casey Klockow L, Nekorchuk M, SharifiHJ, de Noronha CM. 2012. The HIV1 protein Vpr acts to enhance constitutive DCAF1-dependent UNG2 turnover. PLoS One 7:e30939. http://dx.doi.org/10.1371/journal.pone.0030939.
39. Schröfelbauer B, Yu Q, Zeitlin SG, Landau NR. 2005. Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases. J. Virol. 79:10978-10987. http://dx.doi.org/10.1128/JVI.79.17.10978-10987.2005.
40. Ahn J, Vu T, Novince Z, Guerrero-Santoro J, Rapic-Otrin V, Gronenborn AM. 2010. HIV-1 Vpr loads uracil DNA glycosylase-2 onto DCAF1, a substrate recognition subunit of a cullin 4A-ring E3 ubiquitin ligase for proteasome-dependent degradation. J. Biol. Chem. 285:37333-37341. http://dx.doi.org/10.1074/jbc. M110.133181.
41. Goh WC, Rogel ME, Kinsey CM, Michael SF, Fultz PN, Nowak MA, Hahn BH, Emerman M. 1998. HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nat. Med. 4:65-71. http://dx.doi.org/10.1038/nm0198-065.
42. Angers S, Li T, Yi X, MacCoss MJ, Moon RT, Zheng N. 2006. Molecular architecture and assembly of the DDB1-CUL4A ubiquitin ligase machinery. Nature 443:590-593. http://dx.doi.org/10.1038/nature 05175.
43. He YJ, McCall CM, Hu J, Zeng Y, Xiong Y. 2006. DDB1 functions as a linker to recruit receptor WD40 proteins to CUL4-ROC1 ubiquitin ligases. Genes Dev. 20:2949-2954. http://dx.doi.org/10.1101/gad.1483206.
44. Higa LA, Banks D, Wu M, Kobayashi R, Sun H, Zhang H. 2006. L2DTL/CDT2 interacts with the CUL4/DDB1 complex and PCNA and regulates CDT1 proteolysis in response to DNA damage. Cell Cycle 5:1675-1680. http://dx.doi.org/10.4161/cc.5.15.3149.
45. Jin J, Arias EE, Chen J, Harper JW, Walter JC. 2006. A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase destruction of the replication factor Cdt1. Mol. Cell 23:709-721. http://dx.doi.org/10.1016/j.molcel.2006.08.010.
46. Ahn J, Novince Z, Concel J, Byeon CH, Makhov AM, Byeon IJ, Zhang P, Gronenborn AM. 2011. The Cullin-RING E3 ubiquitin ligase CRL4-DCAF1 complex dimerizes via a short helical region in DCAF1. Biochemistry 50:1359-1367. http://dx.doi.org/10.1021/bi101749s.
47. Casey L, Wen X, de Noronha CM. 2010. The functions of the HIV1 protein Vpr and its action through the DCAF1.DDB1.Cullin4 ubiquitin ligase. Cytokine 51:1-9. http://dx.doi.org/10.1016/j.cyto.2010.02.018.
48. Bergamaschi A, Ayinde D, David A, Le Rouzic E, Morel M, Collin G, Descamps D, Damond F, Brun-Vezinet F, Nisole S, Margottin-Goguet F, Pancino G, Transy C. 2009. The human immunodeficiency virus type 2 Vpx protein usurps the CUL4A-DDB1 DCAF1 ubiquitin ligase to overcome a postentry block in macrophage infection. J. Virol. 83:4854-4860. http://dx.doi.org/10.1128/JVI.00187-09.
49. Srivastava S, Swanson SK, Manel N, Florens L, Washburn MP, Skowronski J. 2008. Lentiviral Vpx accessory factor targets VprBP/DCAF1 substrate adaptor for cullin 4 E3 ubiquitin ligase to enable macrophage infection. PLoS Pathog. 4:e1000059. http://dx.doi.org/10.1371/journal.ppat.1000059.
50. Le Rouzic E, Morel M, Ayinde D, Belaidouni N, Letienne J, Transy C, Margottin-Goguet F. 2008. Assembly with the Cul4A-DDB1-DCAF1 ubiquitin ligase protects HIV-1 Vpr from proteasomal degradation. J. Biol. Chem. 283:21686-21692. http://dx.doi.org/10.1074/jbc. M710298200.
51. Zou Y, Mi J, Cui J, Lu D, Zhang X, Guo C, Gao G, Liu Q, Chen B, Shao C, Gong Y. 2009. Characterization of nuclear localization signal in the N terminus of CUL4B and its essential role in cyclin E degradation and cell cycle progression. J. Biol. Chem. 284:33320-33332. http://dx.doi.org/10.1074/jbc. M109.050427.
52. Yin Y, Lin C, Kim ST, Roig I, Chen H, Liu L, Veith GM, Jin RU, Keeney S, Jasin M, Moley K, Zhou P, Ma L. 2011. The E3 ubiquitin ligase Cullin 4A regulates meiotic progression in mouse spermatogenesis. Dev. Biol. 356:51-62. http://dx.doi.org/10.1016/j.ydbio.2011.05.661.
53. Badura-Stronka M, Jamsheer A, Materna-Kiryluk A, Sowinska A, Kiryluk K, Budny B, Latos-Bielenska A. 2010. A novel nonsense mutation in CUL4B gene in three brothers with X-linked mental retardation syndrome. Clin. Genet. 77:141-144. http://dx.doi.org/10.1111/j.1399-0004.2009.01331.x.
54. Isidor B, Pichon O, Baron S, David A, Le Caignec C. 2010. Deletion of the CUL4B gene in a boy with mental retardation, minor facial anomalies, short stature, hypogonadism, and ataxia. Am. J. Med. Genet. A152A: 175-180. http://dx.doi.org/10.1002/ajmg.a.33152.
55. Tarpey PS, Raymond FL, O'Meara S, Edkins S, Teague J, Butler A, Dicks E, Stevens C, Tofts C, Avis T, Barthorpe S, Buck G, Cole J, Gray K, Halliday K, Harrison R, Hills K, Jenkinson A, Jones D, Menzies A, Mironenko T, Perry J, Raine K, Richardson D, Shepherd R, Small A, Varian J, West S, Widaa S, Mallya U, Moon J, Luo Y, Holder S, Smithson SF, Hurst JA, Clayton-Smith J, Kerr B, Boyle J, Shaw M, Vandeleur L, Rodriguez J, Slaugh R, Easton DF, Wooster R, Bobrow M, Srivastava AK, Stevenson RE, Schwartz CE, Turner G, Gecz J, Futreal PA, Stratton MR, Partington M. 2007. Mutations in CUL4B, which encodes a ubiquitin E3 ligase subunit, cause an X-linked mental retardation syndrome associated with aggressive outbursts, seizures, relative macrocephaly, central obesity, hypogonadism, pes cavus, and tremor. Am. J. Hum. Genet. 80:345-352. http://dx.doi.org/10.1086/511134.
56. Zou Y, Liu Q, Chen B, Zhang X, Guo C, Zhou H, Li J, Gao G, Guo Y, Yan C, Wei J, Shao C, Gong Y. 2007. Mutation in CUL4B, which encodes a member of cullin-RING ubiquitin ligase complex, causes Xlinked mental retardation. Am. J. Hum. Genet. 80:561-566. http://dx.doi.org/10.1086/512489.
57. Nakagawa T, Xiong Y. 2011. X-linked mental retardation gene CUL4B targets ubiquitylation of H3K4 methyltransferase component WDR5 and regulates neuronal gene expression. Mol. Cell 43:381-391. http://dx.doi.org/10.1016/j.molcel.2011.05.033.
58. Chen LC, Manjeshwar S, Lu Y, Moore D, Ljung BM, Kuo WL, Dairkee SH, Wernick M, Collins C, Smith HS. 1998. The human homologue for the Caenorhabditis elegans cul-4 gene is amplified and overexpressed in primary breast cancers. Cancer Res. 58:3677-3683.
59. Yasui K, Arii S, Zhao C, Imoto I, Ueda M, Nagai H, Emi M, Inazawa J. 2002. TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas. Hepatology 35:1476-1484. http://dx.doi.org/10.1053/jhep.2002.33683.
60. Hung MS, Mao JH, Xu Z, Yang CT, Yu JS, Harvard C, Lin YC, Bravo DT, Jablons DM, You L. 2011. Cul4A is an oncogene in malignant pleural mesothelioma. J. Cell. Mol. Med. 15:350-358. http://dx.doi.org/10.1111/j.1582-4934.2009.00971.x.
61. Liu L, Lee S, Zhang J, Peters SB, Hannah J, Zhang Y, Yin Y, KoffA, Ma L, Zhou P. 2009. CUL4A abrogation augments DNA damage response and protection against skin carcinogenesis. Mol. Cell 34:451-460. http://dx.doi.org/10.1016/j.molcel.2009.04.020.
62. Zimmerman ES, Sherman MP, Blackett JL, Neidleman JA, Kreis C, Mundt P, Williams SA, Warmerdam M, Kahn J, Hecht FM, Grant RM, de Noronha CM, Weyrich AS, Greene WC, Planelles V. 2006. Human immunodeficiency virus type 1 Vpr induces DNA replication stress in vitro and in vivo. J. Virol. 80:10407-10418. http://dx.doi.org/10.1128/JVI.01212-06.
63. Roshal M, Kim B, Zhu Y, Nghiem P, Planelles V. 2003. Activation of the ATR-mediated DNA damage response by the HIV-1 viral protein R. J. Biol. Chem. 278:25879-25886. http://dx.doi.org/10.1074/jbc. M30394 8200.
64. Tachiwana H, Shimura M, Nakai-Murakami C, Tokunaga K, Takizawa Y, Sata T, Kurumizaka H, Ishizaka Y. 2006. HIV-1 Vpr induces DNA double-strand breaks. Cancer Res. 66:627-631. http://dx.doi.org/10.1158/0008-5472.CAN-05-3144.
65. de Noronha CM, Sherman MP, Lin HW, Cavrois MV, Moir RD, Goldman RD, Greene WC. 2001. Dynamic disruptions in nuclear envelope architecture and integrity induced by HIV-1 Vpr. Science 294: 1105-1108. http://dx.doi.org/10.1126/science.1063957.
66. Moir RD, Spann TP, Herrmann H, Goldman RD. 2000. Disruption of nuclear lamin organization blocks the elongation phase of DNA replication. J. Cell Biol. 149:1179-1192. http://dx.doi.org/10.1083/jcb.149.6.1179.
67. Wei W, Guo H, Han X, Liu X, Zhou X, Zhang W, Yu XF. 2012. A novel DCAF1-binding motif required for Vpx-mediated degradation of nuclear SAMHD1 and Vpr-induced G2 arrest. Cell. Microbiol. 14:1745-1756. http://dx.doi.org/10.1111/j.1462-5822.2012.01835.x.
68. Hofmann H, Logue EC, Bloch N, Daddacha W, Polsky SB, Schultz ML, Kim B, Landau NR. 2012. The Vpx lentiviral accessory protein targets SAMHD1 for degradation in the nucleus. J. Virol. 86:12552-12560. http://dx.doi.org/10.1128/JVI.01657-12.
69. Brandariz-Nunez A, Valle-Casuso JC, White TE, Laguette N, Benkirane M, Brojatsch J, Diaz-Griffero F. 2012. Role of SAMHD1 nuclear localization in restriction of HIV-1 and SIVmac. Retrovirology 9:49. http://dx.doi.org/10.1186/1742-4690-9-49.
70. Morner A, Bjorndal A, Albert J, Kewalramani VN, Littman DR, Inoue R, Thorstensson R, Fenyo EM, Bjorling E. 1999. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J. Virol. 73:2343-2349.
71. Schreiber E, Matthias P, Muller MM, Schaffner W. 1989. Rapid detec-tion of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res. 17:6419. http://dx.doi.org/10.1093/nar/17.15.6419.
72. Chesebro B, Wehrly K, Nishio J, Perryman S. 1992. Macrophagetropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism. J. Virol. 66:6547-6554.
73. Horton R, Spearman P, Ratner L. 1994. HIV-2 viral protein X association with the GAG p27 capsid protein. Virology 199:453-457. http://dx.doi.org/10.1006/viro.1994.1144.
74. Akkina RK, Walton RM, Chen ML, Li QX, Planelles V, Chen IS. 1996. High-efficiency gene transfer into CD34+ cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G. J. Virol. 70:2581-2585.
75. Reil H, Hoxter M, Moosmayer D, Pauli G, Hauser H. 1994. CD4 expressing human 293 cells as a tool for studies in HIV-1 replication: the efficiency of translational frameshifting is not altered by HIV-1 infection. Virology 205:371-375. http://dx.doi.org/10.1006/viro.1994.1655.
76. Balliet JW, Kolson DL, Eiger G, Kim FM, McGann KA, Srinivasan A, Collman R. 1994. Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu, and nef: mutational analysis of a primary HIV-1 isolate. Virology 200:623-631. http://dx.doi.org/10.1006/viro.1994.1225.
77. Connor RI, Chen BK, Choe S, Landau NR. 1995. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206:935-944. http://dx.doi.org/10.1006/viro.1995.1016.
78. Zou Y, Mi J, Wang W, Lu J, Zhao W, Liu Z, Hu H, Yang Y, Gao X, Jiang B, Shao C, Gong Y. 2013. CUL4B promotes replication licensing by up-regulating the CDK2-CDC6 cascade. J. Cell Biol. 200:743-756. http://dx.doi.org/10.1083/jcb.201206065.
79. Kewalramani VN, Park CS, Gallombardo PA, Emerman M. 1996. Protein stability influences human immunodeficiency virus type 2 Vpr virion incorporation and cell cycle effect. Virology 218:326-334. http://dx.doi.org/10.1006/viro.1996.0201.
80. Selig L, Benichou S, Rogel ME, Wu LI, Vodicka MA, Sire J, Benarous R, Emerman M. 1997. Uracil DNA glycosylase specifically interacts with Vpr of both human immunodeficiency virus type 1 and simian immunodeficiency virus of sooty mangabeys, but binding does not correlate with cell cycle arrest. J. Virol. 71:4842-4846.
81. Langevin C, Maidou-Peindara P, Aas PA, Jacquot G, Otterlei M, Slupphaug G, Benichou S. 2009. Human immunodeficiency virus type 1 Vpr modulates cellular expression of UNG2 via a negative transcriptional effect. J. Virol. 83:10256-10263. http://dx.doi.org/10.1128/JVI.02654-08.
82. Priet S, Gros N, Navarro JM, Boretto J, Canard B, Querat G, Sire J. 2005. HIV-1-associated uracil DNA glycosylase activity controls dUTP misincorporation in viral DNA and is essential to the HIV-1 life cycle. Mol. Cell 17:479-490. http://dx.doi.org/10.1016/j.molcel.2005.01.016.
83. Jones KL, Roche M, Gantier MP, Begum NA, Honjo T, Caradonna S, Williams BR, Mak J. 2010. X4 and R5 HIV-1 have distinct post-entry requirements for uracil DNA glycosylase during infection of primary cells. J. Biol. Chem. 285:18603-18614. http://dx.doi.org/10.1074/jbc. M109.090126.
84. Fenard D, Houzet L, Bernard E, Tupin A, Brun S, Mougel M, Devaux C, Chazal N, Briant L. 2009. Uracil DNA glycosylase 2 negatively regulates HIV-1 LTR transcription. Nucleic Acids Res. 37:6008-6018. http://dx.doi.org/10.1093/nar/gkp673.
85. Weil AF, Ghosh D, Zhou Y, Seiple L, McMahon MA, Spivak AM, Siliciano RF, Stivers JT. 2013. Uracil DNA glycosylase initiates degradation of HIV-1 cDNA containing misincorporated dUTP and prevents viral integration. Proc. Natl. Acad. Sci. U. S. A. 110:E448-E457. http://dx.doi.org/10.1073/pnas.1219702110.
86. Kaiser SM, Emerman M. 2006. Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G. J. Virol. 80:875-882. http://dx.doi.org/10.1128/JVI.80.2.875-882.2006.
87. Sleigh R, Sharkey M, Newman MA, Hahn B, Stevenson M. 1998. Differential association of uracil DNA glycosylase with SIVSM Vpr and Vpx proteins. Virology 245:338-343. http://dx.doi.org/10.1006/viro.1998.9159.
88. BouHamdan M, Xue Y, Baudat Y, Hu B, Sire J, Pomerantz RJ, Duan LX. 1998. Diversity of HIV-1 Vpr interactions involves usage of the WXXF motif of host cell proteins. J. Biol. Chem. 273:8009-8016. http://dx.doi.org/10.1074/jbc.273.14.8009.
89. Bouhamdan M, Benichou S, Rey F, Navarro JM, Agostini I, Spire B, Camonis J, Slupphaug G, Vigne R, Benarous R, Sire J. 1996. Human immunodeficiency virus type 1 Vpr protein binds to the uracil DNA glycosylase DNA repair enzyme. J. Virol. 70:697-704.
90. Schrofelbauer B, Hakata Y, Landau NR. 2007. HIV-1 Vpr function is mediated by interaction with the damage-specific DNA-binding protein DDB1. Proc. Natl. Acad. Sci. U. S. A. 104:4130-4135. http://dx.doi.org/10.1073/pnas.0610167104.
91. Nekorchuk MD, SharifiHJ, Furuya AK, Jellinger R, de Noronha CM. 2013. HIV relies on neddylation for ubiquitin ligase-mediated functions. Retrovirology 10:138. http://dx.doi.org/10.1186/1742-4690-10-138.
92. Jin J, Ang XL, Shirogane T, Wade Harper J. 2005. Identification of substrates for F-box proteins. Methods Enzymol. 399:287-309. http://dx.doi.org/10.1016/S0076-6879(05)99020-4.
93. St Gelais C, de Silva S, Amie SM, Coleman CM, Hoy H, Hollenbaugh JA, Kim B, Wu L. 2012. SAMHD1 restricts HIV-1 infection in dendritic cells (DCs) by dNTP depletion, but its expression in DCs and primary CD4+T-lymphocytes cannot be upregulated by interferons. Retrovirology 9:105. http://dx.doi.org/10.1186/1742-4690-9-105.
94. Hofmann H, Norton TD, Schultz ML, Polsky SB, Sunseri N, Landau NR. 2013. Inhibition of CUL4A neddylation causes a reversible block to SAMHD1-mediated restriction of HIV-1. J. Virol. 87:11741-11750. http://dx.doi.org/10.1128/JVI.02002-13.
95. Wei W, Guo H, Liu X, Zhang H, Qian L, Luo K, Markham RB, Yu XF. 2014. A first-in-class NAE inhibitor, MLN4924, blocks lentiviral infection in myeloid cells by disrupting neddylation-dependent Vpxmediated SAMHD1 degradation. J. Virol. 88:745-751. http://dx.doi.org/10.1128/JVI.02568-13.
96. Hagen L, Kavli B, Sousa MM, Torseth K, Liabakk NB, Sundheim O, Pena-Diaz J, Otterlei M, Horning O, Jensen ON, Krokan HE, Slupphaug G. 2008. Cell cycle-specific UNG2 phosphorylations regulate protein turnover, activity and association with RPA. EMBO J. 27:51-61. http://dx.doi.org/10.1038/sj.emboj.7601958.
97. Hardeland U, Kunz C, Focke F, Szadkowski M, Schar P. 2007. Cell cycle regulation as a mechanism for functional separation of the apparently redundant uracilDNAglycosylases TDG and UNG2. Nucleic Acids Res. 35:3859-3867. http://dx.doi.org/10.1093/nar/gkm337.
98. Pham TN, Richard J, Gerard FC, Power C, Cohen EA. 2011. Modulation of NKG2D-mediated cytotoxic functions of natural killer cells by viral protein R (Vpr) from HIV-1 primary isolates. J. Virol. 85:12254-12261. http://dx.doi.org/10.1128/JVI.05835-11.
99. Richard J, Sindhu S, Pham TN, Belzile JP, Cohen EA. 2010. HIV-1 Vpr up-regulates expression of ligands for the activating NKG2D receptor and promotes NK cell-mediated killing. Blood 115:1354-1363. http://dx.doi.org/10.1182/blood-2009-08-237370.
100. Ward J, Davis Z, DeHart J, Zimmerman E, Bosque A, Brunetta E, Mavilio D, Planelles V, Barker E. 2009. HIV-1 Vpr triggers natural killer cell-mediated lysis of infected cells through activation of the ATRmediated DNA damage response. PLoS Pathog. 5:e1000613. http://dx.doi.org/10.1371/journal.ppat.1000613.
101. Coley W, Van Duyne R, Carpio L, Guendel I, Kehn-Hall K, Chevalier S, Narayanan A, Luu T, Lee N, Klase Z, Kashanchi F. 2010. Absence of DICER in monocytes and its regulation by HIV-1. J. Biol. Chem. 285: 31930-31943. http://dx.doi.org/10.1074/jbc. M110.101709.
102. Casey Klockow L, SharifiHJ, Wen X, Flagg M, Furuya AK, Nekorchuk M, de Noronha CM. 2013. The HIV-1 protein Vpr targets the endoribonuclease Dicer for proteasomal degradation to boost macrophage infection. Virology 444:191-202. http://dx.doi.org/10.1016/j.virol.2013.06.010.
103. Guo H, Wei W, Wei Z, Liu X, Evans SL, Yang W, Wang H, Guo Y, Zhao K, Zhou JY, Yu XF. 2013. Identification of critical regions in human SAMHD1 required for nuclear localization and Vpx-mediated degradation. PLoS One 8:e66201. http://dx.doi.org/10.1371/journal.pone.0066201.
104. Laguette N, Rahm N, Sobhian B, Chable-Bessia C, Munch J, Snoeck J, Sauter D, Switzer WM, Heneine W, KirchhoffF, Delsuc F, Telenti A, Benkirane M. 2012. Evolutionary and functional analyses of the interaction between the myeloid restriction factorSAMHD1and the lentiviral Vpx protein. Cell Host Microbe 11:205-217. http://dx.doi.org/10.1016/j.chom.2012.01.007.
105. Baldauf HM, Pan X, Erikson E, Schmidt S, Daddacha W, Burggraf M, Schenkova K, Ambiel I, Wabnitz G, Gramberg T, Panitz S, Flory E, Landau NR, Sertel S, Rutsch F, Lasitschka F, Kim B, Konig R, Fackler OT, Keppler OT. 2012. SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells. Nat. Med. 18:1682-1687. http://dx.doi.org/10.1038/nm.2964.
106. Pertel T, Reinhard C, Luban J. 2011. Vpx rescues HIV-1 transduction of dendritic cells from the antiviral state established by type 1 interferon. Retrovirology 8:49. http://dx.doi.org/10.1186/1742-4690-8-49.
107. Reinhard C, Bottinelli D, Kim B, Luban J. 2014. Vpx rescue of HIV-1 from the antiviral state in mature dendritic cells is independent of the intracellular deoxynucleotide concentration. Retrovirology 11:12. http://dx.doi.org/10.1186/1742-4690-11-12.
108. Bennett EJ, Rush J, Gygi SP, Harper JW. 2010. Dynamics of cullin-RING ubiquitin ligase network revealed by systematic quantitative proteomics. Cell 143:951-965. http://dx.doi.org/10.1016/j.cell.2010.11.017.